Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, PWRM's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of PWRM, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."
"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
WellCare Health Plans, Inc. (NYSE:WCG)
WCGB's Alec Cunningham, Chief Executive Officer, participated in a panel discussion at the Stifel Nicolaus 2010 Healthcare Conference. The discussionwas titled “Managed Care – New Markets and Mix?”. A replay of the webcast is for 30 days via WCGy’s website.
WCG provides managed care services for government-sponsored healthcare programs in the United States. WCG offers Medicaid and Medicare plans, including health plans for families, children, aged, blind, and disabled, as well as prescription drug plans. WCG's Medicaid plans include plans for individuals who are dually eligible for Medicare and Medicaid; and beneficiaries of the Temporary Assistance to Needy Families program (TANF), Supplemental Security Income Program (NYSE:SSI), ABD program, State Children's Health Insurance program (S-CHIP), and the Family Health Plus program(FHP). The TANF program provides assistance to low-income families with children; the SSI and ABD program offers assistance to low-income aged, blind, and disabled individuals; and the S-CHIP and FHP programs provides assistance for families not eligible for Medicaid. WCG's Medicare plans include stand-alone prescription drug plans; and Medicare Advantage plans comprising coordinated care plans (NYSE:CCP). The Medicare Advantage is Medicare's managed care alternative to original Medicare fee-for-service that provides individuals standard Medicare benefits through Centers for Medicare & Medicaid Services. CCPs are administered through a health maintenance organization and require members to seek health care services from a network of health care providers. As of December 31, 2009, WCG had approximately 1,349,000 Medicaid members and approximately 972,000 Medicare members. WCG was founded in 1985 and is headquartered in Tampa, Florida.
To learn more about WCG visit: http://www.wellcare.com
WellPoint, Inc. (NYSE:WLP)
WLP announced recently that its subsidiary, National Government Services, Inc., was selected by the Centers for Medicare & Medicaid Services (NYSE:CMS) to continue administering the Durable Medical Equipment Medicare Administrative Contract (DME MAC) for Jurisdiction B, which includes the states of Illinois, Indiana, Kentucky, Michigan, Minnesota, Ohio, and Wisconsin.
WLP, through its subsidiaries, operates as a health benefits company in the United States. WLP offers various network-based managed care plans to large and small employer, individual, Medicaid, and senior markets. WLP, formerly known as Anthem, Inc., was founded in 1944 and is based in Indianapolis, Indiana.
To learn more about WLP visit: http://www.wellpoint.com
Wells Fargo & Company (NYSE:WFC)
Wells Fargo Funds Management, LLC, announced today the dividend declaration for the Wells Fargo Advantage Income Opportunities Fund (Amex:EAD), the Wells Fargo Advantage Multi-Sector Income Fund (Amex:ERC) and the Wells Fargo Advantage Utilities and High Income Fund (Amex:ERH).
The Wells Fargo Advantage Income Opportunities Fund is a closed-end high-yield bond fund. The Fund’s investment objective is to seek a high level of current income. The Fund may, as a secondary objective, seek capital appreciation to the extent it is consistent with its investment objective.
WFC, through its subsidiaries, provides retail, commercial, and corporate banking services principally in the United States. WFC operates through three segments: Community Banking; Wholesale Banking; and Wealth, Brokerage, and Retirement. As of December 31, 2009, WFC provided its services through approximately 10,000 banking stores located in 39 states and the District of Columbia. WFC was founded in 1929 and is headquartered in San Francisco, California.
To learn more about WFC visit: http://www.wellsfargo.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (OTC:PWRM). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (OTC:PWRM). Each advertising commitment has now expired.